adenine has been researched along with MS (Multiple Sclerosis) in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, X | 1 |
| Hou, H | 1 |
| Zou, Y | 1 |
| Guo, L | 1 |
| Savic, RM | 1 |
| Novakovic, AM | 1 |
| Ekblom, M | 1 |
| Munafo, A | 1 |
| Karlsson, MO | 1 |
| Heidari, A | 1 |
| Behmanesh, M | 1 |
| Sahraian, MA | 1 |
| Meshkani, R | 1 |
| Darvish, H | 1 |
| Najmabadi, H | 1 |
| Ohadi, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)[NCT00213135] | Phase 3 | 1,326 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A qualifying relapse was defined as an increase of 2 points in at least one functional system of the expanded disability status scale (EDSS) or an increase of 1 point in at least two functional systems (excluding changes in bowel or bladder function or cognition) in the absence of fever, lasting for at least 24 hours and to have been preceded by at least 30 days of clinical stability or improvement. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to multiple sclerosis [MS]) was calculated. The annualized relapse rate for each treatment group was calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25. (NCT00213135)
Timeframe: Week 96
| Intervention | relapses per year (Number) |
|---|---|
| Cladribine 5.25 mg/kg | 0.15 |
| Cladribine 3.5 mg/kg | 0.14 |
| Placebo | 0.33 |
A qualifying relapse was defined as an increase of 2 points in at least one functional system of the EDSS or an increase of 1 point in at least two functional systems (excluding changes in bowel or bladder function or cognition) in the absence of fever, lasting for at least 24 hours and to have been preceded by at least 30 days of clinical stability or improvement. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. (NCT00213135)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| Cladribine 5.25 mg/kg | 78.9 |
| Cladribine 3.5 mg/kg | 79.7 |
| Placebo | 60.9 |
Time to disability progression was defined as the time to a sustained increase in EDSS score of at least 1 point if baseline EDSS score between 0.5 and 4.5 inclusively, or at least 1.5 points if the baseline EDSS score was 0, or at least 0.5 point if the baseline EDSS score was at least 5, over a period of at least three months. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Tenth Percentile of time to sustained increase in EDSS score was reported using Kaplan-Meier survival curve. (NCT00213135)
Timeframe: Baseline up to Week 96
| Intervention | months (Number) |
|---|---|
| Cladribine 5.25 mg/kg | 13.6 |
| Cladribine 3.5 mg/kg | 13.6 |
| Placebo | 10.8 |
Mean Number of CU lesions, active T2 lesions, and active T1 Gd+ lesions were measured by using magnetic resonance imaging (MRI) scans. (NCT00213135)
Timeframe: Week 96
| Intervention | lesions (Least Squares Mean) | ||
|---|---|---|---|
| CU lesions | Active T1 Gd+ lesions | Active T2 lesions | |
| Cladribine 3.5 mg/kg | 0.43 | 0.12 | 0.38 |
| Cladribine 5.25 mg/kg | 0.38 | 0.11 | 0.33 |
| Placebo | 1.72 | 0.91 | 1.43 |
1 trial available for adenine and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis.
Topics: Adenine; Administration, Intravenous; Administration, Oral; Adult; Aged; Cladribine; Double-Blind Me | 2017 |
2 other studies available for adenine and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Defective autophagy is associated with neuronal injury in a mouse model of multiple sclerosis.
Topics: Adenine; Animals; Apoptosis; Autophagy; Beclin-1; Caspase 3; Disease Models, Animal; Encephalomyelit | 2017 |
The human caveolin 1 gene upstream purine complex and neurodegeneration--a common signature.
Topics: Adenine; Case-Control Studies; Caveolin 1; Guanine; Haplotypes; Humans; Multiple Sclerosis; Neurodeg | 2011 |